A Quick Briefing for Prescribers

If your patients are reporting difficulty filling Briviact (brivaracetam) prescriptions, they're not imagining things. While Briviact is not listed on the FDA's official drug shortage database as of early 2026, real-world availability remains inconsistent — particularly at chain pharmacies and in rural areas.

This post is a practical overview for neurologists, epileptologists, and primary care physicians who prescribe or manage patients on Briviact. We'll cover the current supply picture, what's driving the access challenges, and concrete steps you can take to help your patients stay on therapy.

Current Supply Status: March 2026

Briviact is not in a formal FDA shortage. UCB continues to manufacture all three formulations — oral tablets (10 mg through 100 mg), oral solution (10 mg/mL), and IV injection (10 mg/mL).

However, several factors create a gap between "available from the manufacturer" and "available at your patient's pharmacy":

• Limited stocking at chain pharmacies. Many CVS, Walgreens, and Rite Aid locations don't routinely carry Briviact. It's a specialty antiepileptic with relatively low prescription volume compared to levetiracetam or lamotrigine.
• Schedule V classification. As a controlled substance, Briviact is subject to additional inventory management requirements that some pharmacies find burdensome for a low-volume medication.
• Wholesaler distribution patterns. Not all pharmacy wholesaler agreements include Briviact, which can prevent pharmacies from ordering it even when they want to.

The Generic Landscape

In February 2026, Lupin received FDA approval for a generic brivaracetam oral solution. This is a meaningful development, but it comes with caveats:

• Generic tablets are not yet widely available. Several manufacturers (Aurobindo, Zydus, MSN) have received FDA approvals, but broad retail distribution is still ramping up.
• The oral solution generic may help patients who can use that formulation, but many adult patients prefer tablets.
• Even when generics are technically available, pharmacy ordering systems may take months to list and stock them reliably.

Bottom line: generics are coming, but they haven't solved the access problem yet.

Prescribing Implications

For patients already stabilized on Briviact, continuity matters. Seizure medications carry real risks when interrupted — breakthrough seizures can mean lost driving privileges, workplace injuries, or status epilepticus.

Here are prescribing strategies that can help:

1. Write for Brand and Generic

Consider writing prescriptions that allow both brand and generic dispensing. This gives the pharmacy flexibility to fill with whatever they can source. If your patient has a clinical reason to stay on brand (such as sensitivity to formulation changes), document it clearly.

2. Use Longer Prescription Windows

When appropriate, write 90-day prescriptions rather than 30-day. This reduces the frequency of the "pharmacy doesn't have it" problem and gives patients a buffer. Some states have limitations on controlled substance prescription duration, so check your local regulations.

3. Identify Reliable Pharmacies Proactively

Rather than waiting for patients to call with fill problems, consider directing them to pharmacies known to stock Briviact. Independent pharmacies and specialty pharmacies often have more flexible ordering capabilities. Tools like Medfinder for Providers can help locate pharmacies with current stock.

4. Have a Backup Plan Documented

For patients who might face supply disruptions, document an alternative medication plan in their chart. Common alternatives include:

• Levetiracetam (Keppra) — same SV2A mechanism, widely available, but many Briviact patients switched away due to behavioral side effects
• Lacosamide (Vimpat) — different mechanism (sodium channel), generally well-tolerated
• Perampanel (Fycompa) — AMPA receptor antagonist, another adjunctive option

Having this documented means if a patient calls your office on a Friday afternoon unable to fill their prescription, your staff can authorize the backup without delay.

Cost and Access Barriers

Even when Briviact is physically available, cost can be a barrier. Brand Briviact has a cash price of roughly $1,200 to $2,000 per month depending on dose and pharmacy. Key things to know about financial access:

• UCB Savings Card: Commercially insured patients may pay as little as $10 per prescription. Not valid for Medicare, Medicaid, or Tricare patients.
• UCB Patient Assistance Program: Provides Briviact at no cost to eligible uninsured or underinsured patients. Applications available at briviact.com or through UCB's financial assistance portal.
• Prior authorization: Most commercial insurers and Medicare Part D plans require prior authorization. Many require step therapy through levetiracetam first. Having documentation of levetiracetam intolerance streamlines approvals.
• Generic pricing: As generics become available, cash prices are expected to drop to the $200–$600/month range, though this varies by pharmacy.

For a deeper dive on patient savings options, see our guide: How to Save Money on Briviact.

Tools and Resources for Your Practice

Here are practical resources you can share with your clinical team:

• Medfinder for Providers — Real-time pharmacy stock lookup for Briviact and other hard-to-find medications
• UCB Medical Information: 1-866-822-0068 for product availability questions
• FDA Drug Shortage Database: accessdata.fda.gov — check for any new shortage listings
• Specialty pharmacy networks: Consider establishing relationships with 1-2 specialty pharmacies that reliably stock neurology medications

Looking Ahead

The Briviact availability picture should improve through 2026 and into 2027 as generic competition increases. Multiple manufacturers have ANDA approvals, and retail distribution channels will mature. In the meantime, proactive prescribing practices and reliable pharmacy partnerships are the best tools available.

If you're seeing patterns of access problems among your Briviact patients, you're not alone. The situation is a byproduct of a medication that's clinically important but commercially niche — exactly the kind of drug that falls through the cracks of standard pharmacy stocking models.

For patient-facing information about Briviact availability, you can direct patients to: Briviact Shortage Update: What Patients Need to Know.